TRPV1 is a physical component of the natriuretic peptide A, cGMP, and PKG signalling complex; drug inhibition of TRPV1 could reverse pre-established hypertrophy by TAC. The gene discussed is TRPV1; the disease is persistent truncus arteriosus.